Max Nisen

Analyst

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Latest

Last Flights From Europe Arrive Ahead Of Travel Ban Announced By President Trump

Bloomberg Opinion

American Travel Rules Discriminate Against Europeans

Entry to the U.S. requires more proof of vaccination than should be necessary, while unvaccinated people are free to fly anywhere within the country.

October 20, 2021

October 20, 2021

OpinionBrooke Sutherland and Max Nisen

American Travel Rules Discriminate Against Europeans

Entry to the U.S. requires more proof of vaccination than should be necessary, while unvaccinated people are free to fly anywhere within the country.

Last Flights From Europe Arrive Ahead Of Travel Ban Announced By President Trump

October 19, 2021

October 19, 2021

OpinionMax Nisen

By Allowing Vaccine Mixing, the FDA Simplifies the Booster Rollout

In a shift toward much-needed flexibility, drug regulators will enable all Americans seeking greater protection against Covid-19 to easily get it.

Baltimore Orioles v Chicago White Sox - Game One

October 18, 2021

October 18, 2021

OpinionMax Nisen

Colin Powell’s Death Argues for Vaccines, Not Against Them

The former military officer and statesman needed as many people around him as possible to be vaccinated to diminish his chances of encountering the virus.

Coli Powell

October 7, 2021

October 7, 2021

OpinionSam Fazeli and Max Nisen

Who Will Take Merck’s New Covid-19 Pills?

The antivirals may be approved before year’s end. But healthy people under 65 may not get them.

Virginia Coronavirus Testing Site Opens With No Appointments Needed

October 1, 2021

October 1, 2021

OpinionMax Nisen

Merck’s New Antiviral Promises to Make Covid Less Deadly

It should also be relatively easy to scale up manufacturing and get pills out to the people who need them worldwide.

Pharmaceutical Production Inside Merck KGaA Health Care Laboratory

September 29, 2021

September 29, 2021

OpinionMax Nisen

Crispr Is Still Promising, Even If Editas’s Experiment Falls Short

One attempt to repair a faulty eye gene had disappointing results, but the technology can be expected to one day treat all sorts of genetic diseases.

dpa-story: Crispr

September 27, 2021

September 27, 2021

OpinionMax Nisen

Unproven Covid Pills Could Be Biden's Secret Weapon

Highly convenient oral drugs could be a pandemic game changer. With enough investment, the U.S. could make a whole lot of them for the world.

President Biden Holds Meeting With Business Leaders And CEOs On Covid-19 Response

September 24, 2021

September 24, 2021

OpinionMax Nisen

Liars May Get Covid Boosters Before Those in Need

U.S. experts had a difficult series of decisions to make about boosters based on limited data. But it’s hard to say their final advice is clear, evidence-based or in the best interests of public health.

The U.S. booster rollout, already a messy process, now may be leaving some very vulnerable people at risk.

September 9, 2021

September 9, 2021

OpinionSam Fazeli and Max Nisen

12 of Today’s Most Pressing Covid Questions Answered

From the need for boosters to kids and Covid and the risk of new variants, here’s what you need to know.

We don’t have all of the answers about Covid-19, but we’re learning more every day.

September 1, 2021

September 1, 2021

OpinionMax Nisen

Biden's Rushed Booster Plan Is Already Getting Messy

Setting a timeline before experts weighed in put improper pressure on scientific agencies, raised expectations and now risks creating confusion when the focus should be on first shots.

President Biden Delivers Remarks On Covid-19 And Vaccination

August 25, 2021

August 25, 2021

OpinionMax Nisen

Can Delta Air Lines Make Unvaccinated Workers Pay Up?

The airline is the first major corporation to say it will slap a big health-insurance surcharge on workers who haven’t had their Covid-19 shots. Is this a good idea?

U.S. Airlines Step Up Pilot Recalls As Travel Demand Rebounds

August 19, 2021

August 19, 2021

OpinionMax Nisen

Cancer-Test Deal Plays Chicken With Regulators

Illumina closes its $8 billion acquisition of Grail despite continuing antitrust scrutiny in the U.S. and Europe.

Cirina Ltd. Co-Founder Dennis Lo Interview And Cancer Research Facility

August 13, 2021

August 13, 2021

OpinionMax Nisen and Liam Denning

Moderna Achieves a Tesla-Like Aura With Investors

What could possibly unite a drug developer with a manufacturer of electric cars? It’s all in the narrative.

Moderna / Tesla

August 12, 2021

August 12, 2021

OpinionMax Nisen

We Need Quicker Tests to Contain the Delta Variant

The rise of the delta variant makes testing more important than ever, even among the vaccinated. Rapid antigen tests are the right tool for the job.

Corona rapid tests in Nuremberg school

August 10, 2021

August 10, 2021

OpinionMax Nisen

How Scary Is the Summer Sunscreen Scare?

Recent reports about possible carcinogens in certain sunscreens have raised safety concerns, but don't overreact. Here’s what you need to know.

RF Sun lotion sunscreen sun screen

August 10, 2021

August 10, 2021

OpinionMax Nisen

Can Moderna Buy Its Way Into the $200 Billion Club?

The company needs to put its Covid vaccine windfall to use, but it has outlined an acquisition strategy that won't pay off anytime soon.

In this photo illustration the American pharmaceutical and

August 4, 2021

August 4, 2021

OpinionMax Nisen

A Big Booster Push Now Would Be Wrong and Dangerous

The World Health Organization is right to call for a halt to booster shots until more people in the developing world get their first vaccinations.

World Health Organisation Update On COVID-19 Situation

August 3, 2021

August 3, 2021

OpinionMax Nisen

New York's Vaccine Mandate Should Be the Norm

Requiring proof of inoculation for certain indoor events offers the best chance of increasing vaccine uptake and stopping the spread of the virus.

De Blasio

August 3, 2021

August 3, 2021

OpinionMax Nisen

Louis Pasteur's Vaccine Successor Bets on mRNA

Vaccine giant Sanofi is buying out its partner in mRNA development, Translate Bio, in another validation of the promise of the technology.

Billionaire LVMH Moet Hennessy Louis Vuitton SE Chairman Bernard Arnault at VivaTech 2021

August 2, 2021

August 2, 2021

OpinionMax Nisen

Would You Get a Covid Shot For a Lower Health Bill?

U.S. vaccination rates are still too low. Employers could start offering health-insurance discounts as an incentive to get a shot.

Federal Worker Unions Back Vaccine Mandates Amid Local Backlash